Purple Biotech Reports Results Of CM24 Dose Escalation In Advanced Pancreatic Cancer Patients
Portfolio Pulse from Happy Mohamed
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has announced the completion of its Phase 1 dose escalation study of CM24, a first-in-class anti-CEACAM1 monoclonal antibody addressing multiple tumor types. The study involved 11 pancreatic ductal adenocarcinoma (PDAC) patients and the results showed that the investigational immunotherapy combination was well tolerated across all dose levels with no recorded Drug Limiting Toxicities. The company is now conducting a Phase 2 randomized study of CM24 in collaboration with Bristol Myers Squibb.
July 11, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Purple Biotech's successful completion of the Phase 1 study of CM24 and the initiation of the Phase 2 study could potentially boost investor confidence and positively impact the company's stock price.
The successful completion of the Phase 1 study of CM24 and the initiation of the Phase 2 study indicates progress in Purple Biotech's product pipeline. This could potentially boost investor confidence in the company's ability to bring new products to market, which could positively impact the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100